These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1243 related items for PubMed ID: 29411536

  • 1. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P.
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [Abstract] [Full Text] [Related]

  • 2. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, Hofman P.
    PLoS One; 2017 Apr; 12(8):e0183023. PubMed ID: 28797130
    [Abstract] [Full Text] [Related]

  • 3. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B, Wang WL, Gong Y, Zhao J, Kalhor N, Prieto V, Staerkel G, Roy-Chowdhuri S.
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [Abstract] [Full Text] [Related]

  • 4. Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
    Ilié M, Ngo-Mai M, Long-Mira E, Lassalle S, Butori C, Bence C, Hamila M, Hofman V, Hofman P.
    J Vis Exp; 2018 Sep 25; (139):. PubMed ID: 30320751
    [Abstract] [Full Text] [Related]

  • 5. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC, Ancevski Hunter K, Kurland BF, Abberbock S, Herbst C, Dacic S.
    Histopathology; 2019 Jan 25; 74(2):269-275. PubMed ID: 30105871
    [Abstract] [Full Text] [Related]

  • 6. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A.
    Cancer Cytopathol; 2017 Dec 25; 125(12):896-907. PubMed ID: 29024471
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
    Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K.
    Appl Immunohistochem Mol Morphol; 2016 Jul 25; 24(6):392-7. PubMed ID: 27333219
    [Abstract] [Full Text] [Related]

  • 11. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD, Abengozar-Muela M, Echeveste JI, Subtil JC, Bertó J, Gúrpide A, Calvo A, de Andrea CE.
    Cancer Cytopathol; 2019 Jul 25; 127(7):470-480. PubMed ID: 31245924
    [Abstract] [Full Text] [Related]

  • 12. Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC.
    Torlakovic E, Albadine R, Bigras G, Boag A, Bojarski A, Cabanero M, Camilleri-Broët S, Cheung C, Couture C, Craddock KJ, Cutz JC, Dhamanaskar P, Fiset PO, Hossain M, Hwang DM, Ionescu D, Itani D, Kelly MM, Kwan K, Lim HJ, Nielsen S, Qing G, Sekhon H, Spatz A, Waghray R, Wang H, Xu Z, Tsao MS.
    J Thorac Oncol; 2020 Aug 25; 15(8):1328-1337. PubMed ID: 32304736
    [Abstract] [Full Text] [Related]

  • 13. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.
    J Clin Oncol; 2017 Dec 01; 35(34):3867-3876. PubMed ID: 29053400
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
    Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, Tomii K.
    Anticancer Res; 2018 Dec 01; 38(12):6891-6895. PubMed ID: 30504406
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
    Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner MC, Moretta F, Pegoraro MC, Cavazza A, Samogin G, Furlan V, Mariotti FR, Vacca P, Moretta L, Bogina G.
    Am J Surg Pathol; 2018 Oct 01; 42(10):1384-1389. PubMed ID: 29901568
    [Abstract] [Full Text] [Related]

  • 19. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
    Batenchuk C, Albitar M, Zerba K, Sudarsanam S, Chizhevsky V, Jin C, Burns V.
    J Clin Pathol; 2018 Dec 01; 71(12):1078-1083. PubMed ID: 30275099
    [Abstract] [Full Text] [Related]

  • 20. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB.
    J Thorac Oncol; 2017 May 01; 12(5):878-883. PubMed ID: 28104537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.